TNFα Blockade in Rheumatoid Arthritis — Time for Caution or Enthusiasm?

Pincus T. The underestimated long-term medical and economic consequences of RA. Drugs 1995; 50 (suppl I):1–14

Maini RN , Taylor P.C. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med 2000; 51: 207–229

Feldmann M , Brennan RM , Maini R.N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397–440

McInnes IB Leung B , Liew F.Y. Cell-cell interactions in synovitis: Interactions between T lymphocytes and synovial cells. Arthritis Res; 2000. 2: 374–78.

Scott DTL , Shipley M , Dawson A The clinical management of rheumatoid arthritis and osteoarthritis: Strategies for improving clinical effectiveness. Br J Rheum 1998; 37: 546–54

Fuchs HA , Kaye JJ , Callahan LF Evidence of significant radiographic damage in RA within the first 2 years of disease. J Rheumatol 1989; 16: 585–591

Fuchs HA , Pincus T. Radiographic damage in RA: description by non-linear models. J Rheumatol 1992; 19: 1655–58

Egesmose C , Lund B , Borg G Patients with rheumatoid arthritis benefit from early second line treatment: 5-year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208–13

Munro R , Hampson R , McEntegert A , Thomson EA , Madhok R , Capell HA . Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: Results of a 5 year prospective study. Ann Rheum Dis 1998; 57 (2): 88–93

Maini R , St Clair EW , Breedveld F , Furst D , Kalden J , Weisman M (for the ATTRACT group). Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932–39

Weinblatt ME , Kremer JM , Bankliurst AD , Bulpitt KJ , Fleischmann RM , Fox RK , Jackson CG A trial of etanercept, a recombinant Tumour Necrosis Factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. NEJM 1999; 340 (4): 253–59

O'Dell JR , Haire CE , Erikson N , Drymalski W , Palmer W , Eckhoff P Treatment of rheumatoid arthritis with methotrexate alone, sulphasalazine and hydroxychloroquine or a combination of all 3 medications. NEJM 1996; 334 (20): 1287–1291

Weinblatt ME , Kremer JM , Coblyn JS , Maier AL , Helfgott SM , Morrell M. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42 (7): 1322–28

Tugwell P , Pincus T , Yocum D , Stein M , Gluck O , Kraag G Combination treatment with cyclosporin A and methotrexate in severe rheumatoid arthritis. New Engl J Med 1995; 333 (3): 137–141.

O'Dell R , Leff R , Paulson G , Haire C , Mallek J , Eckhoff PJ Methotrexate (M)hydroxychloroquine H Sulphasalazine (S) versus M-H or M-S for rheumatoid arthritis (RA): Results of a double blind study. Arthritis Rheum 1999; 42 (9 suppl): S 117, abs 282

Bathon JM , Martin R.W. Roy M A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93

McFarlane AC , Brooks PM . An analysis of the relationship between psychological morbidity and disease activity in rheumatoid arthritis. J Rheumatol 1988; 15: 928–31

McEntegert A , Morrison E , Capell HA , Duncan MR , Porter D , Madhok R , Thomson EA . The effect of social deprivation on disease severity and outcome in patients with RA. Ann Rheum Dis 1997; 56: 410–413.

Young A , Williams P , Dixey J , Cox N , Davies P , DevIin J How many patients with early rheumatoid arthritis are likely to need TNF alpha blocking drugs? Results from a prospective study of 926 patients over 5 years. Arthritis Rheum 2000; 43 (suppl): 227 abs 965

Felson DT , Anderson JJ , Meenan RF . Use of short term efficacy/toxicity trade offs to select second line drugs in RA. A metaanalysis of published clinical trials. Arthritis Rheum 1992; 35 (10): 1117–1125

Kraan MC , Versendaal H , Jonker M , Bresnihan B , Post WJ , Hart BA Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998; 41 (8): 1481–88

Smolen JS , Breedveld FC , Burinester GR , Combe B , Emery P , Kalden JR Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000; 59: 504–505

Gershon S , Wise RP , Nui M , Rockville JS . Post licensure reports of infection during use of etanercept and infliximab. Arthritis Rheum 2000; 43: Late breaking abstract.

Perez T , Remy-Jardin M , Corlet B. Airways involvement in rheumatoid arthritis: clinical, functional and HRCT findings. Am J Resp and Crit Care Med 1998; 157: 1658–65

Charles PJ , Smeenk RLT , De Jong J , Feldmann M , Maini R.N. Assessment of antibodies to double stranded DNA in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a. Arthritis Rheum 2000; 43 (11)2383–2390

Choi HK , Seeger JD , Kuntz KM . A cost effectiveness analysis of treatment options for patients with methotrexate resistant rheumatoid arthritis. Arthritis Rheum 2000; 43 (10): 2316–2327

Krause D , Schleusser B , Herborn G , Rau R. Response to methotrexate is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000;(43): 1421

Lehtinen K , Isomaki H. Intramuscular Gold therapy is associated with long survival in patient with rheumatoid arthritis. J Rheumatol 1991; 18: 524–27